Biodexa Pharmaceuticals

Historical price data

Biodexa Pharmaceuticals is a clinical-stage biotechnology company leveraging proprietary drug delivery technologies to improve the performance of existing therapeutic agents. Its strategy centers on reformulating known drugs using nanotechnology and pH-sensitive polymers to enhance bioavailability and pharmacokinetics, thereby de-risking development. The company's pipeline is advancing towards a pivotal Phase 3 trial for eRapa in FAP, while also exploring molecular glue degraders for resistant cancers and a novel therapy for type 1 diabetes. With an experienced leadership team, Biodexa aims to address significant unmet needs in oncology and rare diseases.

Proprietary drug delivery systems utilizing nanotechnology, pH-sensitive polymers for reformulation, and molecular glue degraders for targeted protein degradation.